Sugi Predict

Sugi Predict / Compounds / SCHEMBL433482

SCHEMBL433482

SCHEMBL433482

Fc1cccc(C2CCCCN2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ CHRNB2 P17787 2/20 0.54
▸ CHRNA7 P36544 2/20 0.54
▸ CHRNA4 P43681 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2A6 P11509 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PARP1 P09874 3/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ CLK2 P49760 1/20 0.41
▸ MAP4K2 Q12851 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29450150 0.95 CHRNB2 (0.53) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL3503155 0.95 CHRNB2 (0.53) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL166716 0.95 CHRNB2 (0.53) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL433220 0.95 CHRNB2 (0.53) MEN1CYP2D6CYP2C19KMT2ACHRNB2
Hydrochloric Acid SCHEMBL450686 0.93 CHRNB2 (0.51) MEN1CYP2D6CYP2C19KMT2ACHRNB2
Hydrochloric Acid SCHEMBL450685 0.93 CHRNB2 (0.51) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL21523837 0.85 CHRNB2 (0.48) CYP2D6CHRNB2CHRNA4
SCHEMBL29891721 0.85 CHRNB2 (0.41) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL2708320 0.82 MEN1 (0.47) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL432589 0.81 CA1 (0.39) MEN1CYP2D6CYP2C19KMT2ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
US-10590139-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA INC. (US) 2020-03-17 — — US disclosed
US-20190169193-A1 Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds ARRAY BIOPHARMA INC. 2019-06-06 — — US disclosed
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA, INC. (US) 2018-07-03 — — US disclosed
EP-2451812-B1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2017-11-08 — — EP disclosed
US-9796723-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA, INC. (US) 2017-10-24 — — US disclosed
WO-2010138487-A1 BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2010-12-02 — — WO disclosed
WO-2010033941-A1 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-03-25 — — WO disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 — — EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 — — US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 — — US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 — — US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 — — EP disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 — — EP disclosed
CN-1087083-A The intermediates preparation of synthetic 3-amino piperidine derivatives PFIZER (US) 1994-05-25 — — CN disclosed
CN-1053060-A 3-aminopiperidine derivatives and related nitrogen-containing heterocycles PFIZER (US) 1991-07-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds COL2A1, COL1A1, IFNAR1 MEN1 1604/4885CYP2D6 1257/4885CYP2C19 1056/4885
US-20190169193-A1 Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds COL2A1, COL1A1, IFNAR1 MEN1 1604/4885CYP2D6 1257/4885CYP2C19 1056/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 MEN1 4729/4885CYP2D6 2280/4885CYP2C19 1818/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 MEN1 142/4885CYP2D6 33/4885CYP2C19 20/4885
US-10590139-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds COL2A1, COL1A1, IFNAR1 MEN1 1604/4885CYP2D6 1257/4885CYP2C19 1056/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 MEN1 142/4885CYP2D6 33/4885CYP2C19 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.